NMD Pharma has been cleared by the U.S. Food and Drug Administration (FDA) to start a Phase 2b clinical trial testing NMD670, an investigational CIC-1 inhibitor being developed for generalized myasthenia gravis (gMG). Planned to launch in the coming months in the U.S. and Europe, the trial will…
Enspryng (satralizumab), which Chugai Pharmaceutical is testing for generalized myasthenia gravis (gMG), showed a significant benefit in easing disease symptoms and their impact on daily life when used along with standard of care. Positive results from the placebo-controlled Phase 3 LUMINESCE trial (NCT04963270), however, did not…
Higher levels of an immune protein called macrophage migration inhibitory factor (MIF) in the blood are linked to more severe myasthenia gravis (MG) and an increased risk of relapse, according to a study. The findings suggest MIF could be used as a biomarker of MG disease activity, the study’s…
Periocular (around-the-eyeball) injections of triamcinolone, a corticosteroid, may ease early symptoms of ocular myasthenia gravis (MG) and reduce the need for patients to take oral medications that have more potential side effects, a study has found. The study, “A controlled clinical study on efficacy and safety of periocular…
TOL2, a medication being developed by Toleranzia for the treatment of myasthenia gravis (MG), was found to be well tolerated in a preclinical toxicology study, supporting the company’s decision to test it in humans. No side effects were observed when lab animals were given a dose of TOL2…
In 2023, Myasthenia Gravis News brought up-to-date coverage of the latest scientific research and developments in the treatment of myasthenia gravis (MG). Here are the 10 most-read news stories of 2023, along with a brief description of what made them relevant for our readers. We look forward to…
Vyvgart (efgartigimod alfa) has been listed on China’s 2023 National Reimbursement Drug List (NRDL) as a treatment for adults with generalized myasthenia gravis (gMG) who test positive for self-reactive antibodies against the acetylcholine receptor (AChR) protein. Issued each year by China’s National Healthcare Security Administration (NHSA), the NRDL…
Treatment with intravenous immunoglobulin (IVIG) during pregnancy may have helped ease symptoms of a fetal disorder in a girl born to a mother with myasthenia gravis (MG), according to a report from Germany. The woman’s firstborn had developed severe FARAD (or fetal acetylcholine receptor antibody-related disorder), which occurs…
The experimental treatment povetacicept (ALPN-303) may be more effective than current available treatments for myasthenia gravis (MG), according to preclinical data from Alpine Immune Sciences, which is developing the therapy. Specifically, povetacicept outperformed Vyvgart (efgartigimod) and off-label rituximab at reducing disease activity in a mouse model of the…
Negative emotions, a personality trait known as neuroticism, are more likely in people with myasthenia gravis (MG) than those without this disease, and may explain why these patients appear to be more liable to depression and anxiety, a study suggests. MG patients also scored lower than healthy adults for openness…
Get regular updates to your inbox.